Atezolizumab time-varying population PK
Reference paper ↗A two-compartment population PK model representing atezolizumab disposition, clinical covariate effects, time-varying clearance, concentration, and interval exposure.
- Therapeutic
- Atezolizumab
- Modality
- Monoclonal antibody
- Target
- PD-L1 / CD274
- Disease
- Oncology dosing-regimen simulation
- Model type
- PopPK
Complete model workspace
Checking workspace access…
- Parameters
- 23
- States
- 4
- Equations
- 4
- Derived outputs
- 28
Explore this model
Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.
1200 mg every 3 weeks standard dosing
How do dosing interval and time-varying clearance change atezolizumab concentration and weekly exposure? Explore this intervention regimen through Atezolizumab concentration, Cumulative atezolizumab exposure, Time-varying clearance, Current weekly exposure.
Starting result
This result reflects the starting settings. Run your changes to update it.
Result preview could not load
The generated result could not be loaded. The inputs remain available below.
Starting configuration
Time: 0–273 day; step 1
| Input | Default | Available range |
|---|---|---|
| Typical clearance | 0.23 L/day | 0.115–0.345 L/day |
| Typical central distribution volume | 3.25 L | 1.625–4.875 L |
| Typical intercompartmental clearance | 0.603 L/day | 0.3015–0.9045 L/day |
| Typical peripheral distribution volume | 2.88 L | 1.44–4.32 L |
| Typical time to half-maximal change | 62.8 day | 31.4–94.2 day |
Expected readouts
Atezolizumab concentration · Exposure (AUC) (ug*day/mL) · Time varying clearance · Current weekly exposure
Adjustable model parameters
This public explorer exposes 5 curated parameters. Sign in to edit all 23 declared model parameters.
More key parameters (1)
How the model represents the biology
A two-compartment population PK model representing atezolizumab disposition, clinical covariate effects, time-varying clearance, concentration, and interval exposure.
Solid arrows show modeled movement or change; two-headed arrows show reversible exchange; dashed arrows show modulation without material transfer.
Model scope: PD-L1 binding, immune or tumor response, target-mediated disposition, response-driven clearance, and a rolling seven-day AUC are not represented.
Modeled relationships (7)
- IV atezolizumab → Central exposure: IV input (flow)
- Central exposure ↔ Peripheral pool: distribution (reversible exchange)
- Clinical covariates → Central exposure: scales volume (modulation)
- Clinical covariates → Time-varying clearance: scales baseline CL (modulation)
- Elapsed-time factor → Time-varying clearance: changes CL(t) (modulation)
- Central exposure → Time-varying clearance: adjusted CL (loss)
- Central exposure → Exposure readouts: integrates C (production)
Modeled relationships: IV atezolizumab to Central exposure: IV input (flow); Central exposure reversibly exchanges with Peripheral pool: distribution (reversible exchange); Clinical covariates to Central exposure: scales volume (modulation); Clinical covariates to Time-varying clearance: scales baseline CL (modulation); Elapsed-time factor to Time-varying clearance: changes CL(t) (modulation); Central exposure to Time-varying clearance: adjusted CL (loss); Central exposure to Exposure readouts: integrates C (production).
Primary readouts: Atezolizumab concentration; Cumulative exposure; Time-varying clearance; Normalized weekly exposure.
Related models
Research use only — not for patient-specific prediction or dosing advice.
